Biotech entity
pharma is the sole category represented across all 1 tracked stories. RAP-219 is most often covered alongside ADC Therapeutics, which appears in 1 of these 1 story. RAP-219 appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 3 original sources each.
Last mentioned: Mar 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. RAP-219 is most often covered alongside ADC Therapeutics, which appears in 1 of these 1 story. RAP-219 appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 3 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RAP-219. Shared-story counts are live from our verified record — not editorial picks.
Three distinct biotech players—Tenax, ADC Therapeutics, and Rapport—released 2025 year-end results, highlighting a shift from foundational clinical trials to commercial scaling and late-stage readouts. While Tenax advances its Phase 3 LEVEL trial, ADC Therapeutics focuses on ZYNLONTA’s market penetration and Rapport prepares for key data in epilepsy.
RAP-219 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
